It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

The UChicago Medicine team will be led by Odunsi as co-principal investigator and includes Christopher Weber, Savas Tay, and ...

Ongoing Monitoring and Follow-Up The prognosis (predicted outcome) for ischemic cardiomyopathy depends on how severely ...

View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

HCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 Trial of TN-201 Gene ...

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

Researchers have found a new treatment protocol that may help some people with this deadly cancer to survive longer. News 8’s Brittany Noble has details in Thursday’s Health Spotlight.

“We believe this could provide a unique pathway to protect nerves from pain and provide an avenue to identify potential new treatments.” ...

People with hypertrophic cardiomyopathy (HCM) have a greater risk of becoming severely ill from COVID-19. Furthermore, the virus has been found to significantly damage the heart muscle, causing ...